Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2012-12-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of A-lipoic Acid (ALA) on Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion
NCT01056497
Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Gestational Diabetic Patients
NCT01912170
Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients
NCT01857167
The Effect of Alpha Linolenic Acid Intake on Patients With Elevated Glycemic Status
NCT05053347
Low Glycemic Index Diet (With Canola Oil) for Type 2 Diabetics
NCT01348568
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alpha-Linolenic Acid
Meta-Analysis of Randomized Controlled Trials
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Trials greater than one month
* Focusing on ALA and T2DM participants
* Viable endpoint data
Exclusion Criteria
* Non-random treatment allocation
* Less than 1 month
* Lack of suitable control
* Lack of endpoint data
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Unity Health Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vladimir Vuksan
Research Scientist & Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vladimir Vuksan, PhD
Role: PRINCIPAL_INVESTIGATOR
Unity Health Toronto
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALA and GC in T2D
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.